Akineton
(Biperiden)ApprovedSmall molecule
AbbVieAkineton is one of 67 small molecule programs targeting Epilepsy. It is currently in Approved.
2
Indications
5
Total Trials
1
Active Trials
66
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
84 competitors in Epilepsy
#DrugCompanyPhaseTrials
1Vimpat
UCBApproved
Tegretol
NovartisApproved
Trileptal
NovartisApproved
Fycompa
CCatalyst Biosciences
Approved
Lexapro
AbbVieApproved
Briviact
UCBPhase 3
Dilantin
VViatris Specialty LLC
Approved
Ketalar
AAultman Health Foundation
Approved
Xcopri
SSK Life Science, Inc.
Approved
Coumadin
AAbbott
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cocaine Dependence1 trial
Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence
Unknown status·HHospital Universitari Vall d'Hebron Research Institute·Phase 4·NCT00495183·108 enrolled
Efficacy1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
AKINETON
NDA NDA012418
Jan 1, 1982
AKINETON
NDA NDA012003
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Biperiden. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]